Gh Research Plc · NASDAQ:GHRS
Gh Research — Investor Presentation (March 2026)
17 slides from Gh Research's investor presentation, Mar 5, 2026
Slide 1: Ultra-Rapid, Durable Remission in TRD with Minimal Clinic Burden
GH Research PLC (Nasdaq: GHRS) March 2026 Ultra-Rapid, Durable Remission in TRD with Minimal Clinic Burden 2026© GH Research PLC 1
Slide 2: Forward-Looking Statements
Any statements contained herein that do not describe historical facts are forward-looking statements that are based on management’s expectations and are subject to certain factors, risks and uncertainties that may cause actual results, outcomes, timing and performance to differ materially from those
Slide 3: Pipeline
Product Candidate Indication Preclinical Phase 1 Phase 2a Phase 2b Phase 3 Current Status Milestone GH001 Mebufotenin for inhalation administration Treatment-resistant depression (TRD) Phase 2b RDBPC completed Phase 1 PK trial with proprietary device ongoing Phase 3 initiation in 2026 Phase 1 PK tri
Slide 4: Phase 2b Trial Unprecedented Efficacy in TRD
Phase 2b Trial Unprecedented Efficacy in TRD Positioning GH001 as potentially practice-changing GH001 Key Milestones Achieved and Next Steps Pivotal Phase 3 Program Designed in line with the FDA Guidelines and to replicate the Phase 2b data Global Phase 3 start in 2026 Abbreviations: TRD = Treatment
Slide 5: Phase 2b Trial Design with Open-Label Extension
5 Retreatment of up to five GH001 IDRs if patients met retreatment criteriaa Open-Label Extension (OLE) n=81 Randomization 1:1 GH001 IDR Placebo IDR BL 2h Day 1 Primary endpoint ΔMADRS Day 8 During the OLE, patients attended visits at Day 15, Month 1, 2, 3, 4, 5 & 6b Additional clinic visits could b
Slide 6: Primary Endpoint: MADRS Reduction of -15.5 on Day 8 vs Placebo
Primary Endpoint: GH001 Led to Mean MADRS Reduction from Baseline of -15.5 on Day 8a vs Placebo (P<0.0001) aFDA Guidance notes that efficacy with rapid-acting antidepressants generally should be demonstrated within 1 week, supporting a primary efficacy endpoint within this timeframe. Abbreviations:
Slide 7: Key Secondary Endpoint: MADRS Change, GH001 vs Spravato
GH001 vs Placebo Spravato Mono Spravato +AD Spravato Mono Spravato + AD vs Placebo + AD from TRANSFORM-2a Spravato monotherapy (84mg) vs Placebo from TRD4005b Spravato +AD Not reported Key Secondary Endpoint MADRS Total Score Change from Baseline: GH001 and Spravato at Day 2 and Primary Endpoint (Di
Slide 8: Secondary Endpoints: Remission Rates
Remission Rates with GH001 Remission Rates with Spravato monotherapy (84mg) from TRD4005b Note: To-date, no head-to-head comparisons of any other products to any of our product candidates in any clinical trial have been completed; results have been obtained from different trials with different desig
Slide 9: 73% Remission Rate at 6 Months in OLE Completers
9 73% Remission Rate at 6 Months in OLE Completers aIncludes 63 patients who completed the 6-month OLE per protocol (18 patients terminated early are excluded). bApproximately 6 months post-study start (median 168 days from Day 1 of double-blind part). cRemission defined as MADRS total score ≤10. Ab
Slide 10: Remission Rate at 6 Months in OLE Completers
Initial Remitters n=40 Initial Non-Remitters n=23 Percentage of Patients in Remissionc 10 Remission Rate at 6 Monthsa in OLE Completersb a‘6 Months’ or ‘Month 6’ (end of trial) was at approximately 6 months post-study start (median 168 days from Day 1 of double-blind part). bIncludes 63 patients who
Slide 11: 83% Fewer Treatment Visits with GH001 than Spravato
GH001 Treatment visits in 6 months 4 visitsa 23 visitsc,d 73.0% remission at 6 monthsb 83% Fewer Treatment Visits with GH001 than with Spravato® Note: To-date, no head-to-head comparisons of any other products to any of our product candidates have been completed in any clinical trial; results have b
Slide 12: Median Duration of the Psychoactive Experience
Median Duration of the Psychoactive Experience of 11 minutes (Double-Blind & OLE treatments) Note: To-date, no head-to-head comparisons of any other products to any of our product candidates have been completed in any clinical trial; results have been obtained from different trials with different de
Slide 13: Safety in Double-Blind and Open-Label Extension
Abbreviations: OLE = Open-label extension; SAE = Serious adverse event; TEAE = Treatment-emergent adverse event. Safety in Double-Blind and Open-Label Extension 2026© GH Research PLC All patients completed the double-blind part and automatically transitioned to the OLE No TEAEs of suicidal intent or
Slide 14: Reproducibility of MADRS Reduction Demonstrated in Phase 2b Trial
MADRS reduction in the Placebo group following first active treatmenta after entering the OLE, was comparable to the results observed in the GH001 group in the DB part, showing reproducibility of effects. OLE data shows GH001 leads to a consistent and rapid reduction in MADRS after each GH001 treatm
Slide 15: Potential Value-Add for GH001 in TRD
Potential Value-Add for GH001 in TRD Best in Therapeutic Category (TRD) Efficacy: Pbo-adj MADRS Δ of -15.5 with GH001 vs -6.8 with Spravato monotherapya vs ~-4 with oral ADb Length of PsE: Median of 11 mins with GH001 vs ~1.5 hours with Spravatoc No additional psychotherapy/therapist visits with GH0
Slide 16: Three-Layer Protection Strategy
Three-Layer Protection Strategy 16 LAYER 1: REGULATORY EXCLUSIVITY FDA: 5 years (+2.5 years paragraph IV stay) EMA: 10 years (+1 year for new indication) LAYER 2: PATENTS Granted patents and patent applications relating to mebufotenin, including: Novel uses in various disorders (including inhaled, n
Slide 17: Phase 2b Trial Unprecedented Efficacy in TRD
Phase 2b Trial Unprecedented Efficacy in TRD Positioning GH001 as potentially practice-changing GH001 Key Milestones Achieved and Next Steps Pivotal Phase 3 Program Designed in line with the FDA Guidelines and to replicate the Phase 2b data Global Phase 3 start in 2026 17 >> Abbreviations: TRD = Tre